On April 9, 2026 Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reported that it will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, including two oral presentations and two posters.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Having four abstracts accepted at the prestigious SGO annual meeting underscores the importance of the data we are sharing and our commitment to the cancer care continuum," said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. "We are particularly pleased to be presenting the latest Precise MRD data, showing that Precise MRD testing after adjuvant therapy for ovarian cancer was significantly prognostic of recurrence during the monitoring period. Importantly, recurrence risk tracked with the quantitative ctDNA fraction detected by Precise MRD, with elevated risk observed even at ctDNA levels detectable only by an ultrasensitive assay."
The remaining three presentations use data from the Myriad Collaborative Research Registry (MCRR), one of the largest pan-cancer registries accessible for research use, including de-identified data for more than 1.3 million participants. The studies demonstrate Myriad’s commitment to externally driven research that addresses diverse questions with immediate clinical implications:
Germline pathogenic and likely pathogenic variant prevalence is associated with age and ancestry in patients diagnosed with ovarian cancer before age 40;
Ovarian cancer diagnosis varies by Lynch syndrome gene, informing counseling and risk-reducing surgery recommendations;
Universal hereditary cancer screening identifies more individuals at high risk for endometrial cancer compared to age-based screening.
These studies will be presented at the Society of Gynecologic Oncology Annual Meeting on April 10-13 at the Puerto Rico Convention Center in San Juan. Myriad will exhibit at booth #523. For more information, visit: View Source
Myriad Genetics Presentations
Precise MRD
Evaluation of the Relationship of Molecular Residual Disease Testing to Ovarian Cancer Recurrence
Poster Board Number: 1590
Sun., April 12 at 12:00-1:00 pm AST
Presenter: John Nakayama, MD, Allegheny Health Network
MCRR
Prevalence of germline pathogenic variants in patients with endometrial cancer diagnosed before and after 65 years old within a laboratory-based research registry
Rapid Fire Oral I: Genetics Prevention and Surgery
Sat., April 11 – 3:05-3:08 pm AST
Presenter: Kieran Seay, MD, University of Pittsburgh Medical Center
Broad landscape of genetic variants and ancestry associated with ovarian cancer before age forty
Poster Board Number: 1450
Sun., April 12 – 4:00-4:45 pm AST
Presenter: Eliya K. Shachar, MD, University of California, Los Angeles
Age at ovarian cancer diagnosis varies by lynch syndrome gene: a genetic testing laboratory registry study
Focused Forum X: Genetics – Keeping up with the Genes
Mon., April 13 – 9:30-10:30 am AST
Presenter: Ying L. Liu, MD, MPH, Memorial Sloan Kettering Cancer Center
(Press release, Myriad Genetics, APR 9, 2026, View Source [SID1234664294])